SG11201808478RA - Fibrotic treatment - Google Patents
Fibrotic treatmentInfo
- Publication number
- SG11201808478RA SG11201808478RA SG11201808478RA SG11201808478RA SG11201808478RA SG 11201808478R A SG11201808478R A SG 11201808478RA SG 11201808478R A SG11201808478R A SG 11201808478RA SG 11201808478R A SG11201808478R A SG 11201808478RA SG 11201808478R A SG11201808478R A SG 11201808478RA
- Authority
- SG
- Singapore
- Prior art keywords
- victoria
- international
- clayton
- road
- ang
- Prior art date
Links
- 230000003176 fibrotic effect Effects 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 6
- QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000011780 sodium chloride Substances 0.000 abstract 2
- 102000004400 Aminopeptidases Human genes 0.000 abstract 1
- 108090000915 Aminopeptidases Proteins 0.000 abstract 1
- 102400000349 Angiotensin-4 Human genes 0.000 abstract 1
- 101800000737 Angiotensin-4 Proteins 0.000 abstract 1
- JIZRUFJGHPIYPS-SRVKXCTJSA-N Cys-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O JIZRUFJGHPIYPS-SRVKXCTJSA-N 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- YOODOXUTKZODHS-UHFFFAOYSA-N ethyl 2-acetamido-7-hydroxy-4-quinolin-3-yl-4h-chromene-3-carboxylate Chemical compound C1=CC=CC2=CC(C3C4=CC=C(O)C=C4OC(NC(C)=O)=C3C(=O)OCC)=CN=C21 YOODOXUTKZODHS-UHFFFAOYSA-N 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903035A AU2015903035A0 (en) | 2015-07-30 | Fibrotic treatment | |
| PCT/AU2016/050681 WO2017015720A1 (en) | 2015-07-30 | 2016-07-29 | Fibrotic treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808478RA true SG11201808478RA (en) | 2018-10-30 |
Family
ID=57883919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808478RA SG11201808478RA (en) | 2015-07-30 | 2016-07-29 | Fibrotic treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10100311B2 (https=) |
| EP (1) | EP3328384B1 (https=) |
| JP (3) | JP2018527330A (https=) |
| AU (1) | AU2016301113B2 (https=) |
| CA (1) | CA3017028C (https=) |
| HK (1) | HK1256423A1 (https=) |
| SG (1) | SG11201808478RA (https=) |
| WO (1) | WO2017015720A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016259977A1 (en) * | 2015-05-08 | 2017-11-23 | Monash University | 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors |
| CA3017028C (en) | 2015-07-30 | 2020-06-16 | Monash University | Fibrotic treatment |
| AU2018303333B2 (en) * | 2017-07-17 | 2023-02-09 | Monash University | Angiotensin receptor agonists and uses thereof |
| JP2022516611A (ja) * | 2018-12-28 | 2022-03-01 | ザ ジェネラル ホスピタル コーポレイション | 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体 |
| WO2021050089A1 (en) * | 2019-09-09 | 2021-03-18 | Washington State University | Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis |
| TW202143994A (zh) | 2020-02-19 | 2021-12-01 | 美商希皮恩製藥公司 | 環孢素類似物於治療纖維化之用途 |
| EP4440570A1 (en) * | 2021-12-01 | 2024-10-09 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Irap inhibitors for use in the treatment of inflammatory diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ553688A (en) * | 2004-09-09 | 2011-05-27 | Florey Howard Inst | Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase |
| CN101247819A (zh) * | 2005-08-23 | 2008-08-20 | 惠氏公司 | 治疗焦虑症和鉴定抗焦虑剂的方法 |
| WO2009065169A1 (en) * | 2007-11-19 | 2009-05-28 | Howard Florey Institute | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| KR20150028761A (ko) | 2011-12-16 | 2015-03-16 | 타릭스 파마슈티컬스 엘티디. | 섬유증 치료용 안지오텐신 |
| JP2015509483A (ja) * | 2012-02-06 | 2015-03-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | 線維症を治療するためのｐｉ３ｋ阻害剤 |
| JP6327923B2 (ja) | 2014-04-25 | 2018-05-23 | 旭化成株式会社 | ポリアセタール樹脂組成物、及びそれからなる成形体 |
| DE102014114090A1 (de) | 2014-09-29 | 2016-03-31 | Karlsruher Institut für Technologie | Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion |
| US9519061B2 (en) * | 2014-12-26 | 2016-12-13 | Here Global B.V. | Geometric fingerprinting for localization of a device |
| AU2016259977A1 (en) * | 2015-05-08 | 2017-11-23 | Monash University | 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors |
| CA3017028C (en) * | 2015-07-30 | 2020-06-16 | Monash University | Fibrotic treatment |
-
2016
- 2016-07-29 CA CA3017028A patent/CA3017028C/en active Active
- 2016-07-29 AU AU2016301113A patent/AU2016301113B2/en active Active
- 2016-07-29 WO PCT/AU2016/050681 patent/WO2017015720A1/en not_active Ceased
- 2016-07-29 EP EP16829507.9A patent/EP3328384B1/en active Active
- 2016-07-29 JP JP2018504650A patent/JP2018527330A/ja not_active Withdrawn
- 2016-07-29 SG SG11201808478RA patent/SG11201808478RA/en unknown
- 2016-07-29 US US15/747,697 patent/US10100311B2/en active Active
- 2016-07-29 HK HK18115556.4A patent/HK1256423A1/zh unknown
-
2018
- 2018-09-06 US US16/123,898 patent/US10787668B2/en active Active
-
2020
- 2020-07-29 JP JP2020127888A patent/JP7457360B2/ja active Active
- 2020-08-04 US US16/984,996 patent/US11078488B2/en active Active
-
2021
- 2021-07-01 US US17/365,260 patent/US11834663B2/en active Active
-
2022
- 2022-12-15 JP JP2022199857A patent/JP2023030022A/ja active Pending
-
2023
- 2023-10-26 US US18/495,512 patent/US20240084308A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11078488B2 (en) | 2021-08-03 |
| HK1256423A1 (zh) | 2019-09-20 |
| CA3017028C (en) | 2020-06-16 |
| JP2023030022A (ja) | 2023-03-07 |
| WO2017015720A1 (en) | 2017-02-02 |
| US20240084308A1 (en) | 2024-03-14 |
| AU2016301113A1 (en) | 2018-02-22 |
| EP3328384B1 (en) | 2020-07-29 |
| JP2018527330A (ja) | 2018-09-20 |
| EP3328384A1 (en) | 2018-06-06 |
| US20190249179A1 (en) | 2019-08-15 |
| JP2020189845A (ja) | 2020-11-26 |
| EP3328384A4 (en) | 2019-03-06 |
| US20210340547A1 (en) | 2021-11-04 |
| CA3017028A1 (en) | 2017-02-02 |
| JP7457360B2 (ja) | 2024-03-28 |
| US20200362354A1 (en) | 2020-11-19 |
| US11834663B2 (en) | 2023-12-05 |
| US10100311B2 (en) | 2018-10-16 |
| AU2016301113B2 (en) | 2019-10-03 |
| US20180223287A1 (en) | 2018-08-09 |
| US10787668B2 (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808478RA (en) | Fibrotic treatment | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201806985WA (en) | Methods and reagents for prevention and/or treatment of infection | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907199QA (en) | Cancer treatment |